Please assess the completion status of the following clinical trial:

Trial Title: BENEFITS OF ACLIDINIUM BROMIDE IN THE RELIEF OF COPD SYMPTOMS INCLUDING COUGH

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Adult male or non-pregnant, non-lactating female aged ≥40. Women of childbearing potential will follow specific study requirements.~2. Current or ex-cigarette smoker, with a smoking history of at least 10 pack-years~3. Patients with a clinical diagnosis of moderate COPD, with a post bronchodilator test available within 6 months prior to Visit 1 (Screening), with FEV1 ≥50% and \<80% and FEV1/FVC \<70%.~4. Symptomatic patients with a CAT≥10 at Screening and Randomisation Visit (Visit 1 and 2)~5. Clinical Diagnosis of Chronic Bronchitis (defined as presence of cough and sputum production for at least 3 months in each of 2 consecutive years)~6. Patient who is eligible and able to participate in the trial and who consent to do so in writing after the purpose and nature of the investigation have been explained~Exclusion Criteria:~1. History or current diagnosis of asthma.~2. Patients who suffered from a moderate or severe COPD exacerbation in the last year prior to Visit 1 (Screening) or during the run-in period.~3. Patients who develop a respiratory tract infection within 6 weeks before Visit 1 (Screening) or during the run-in period.~4. Clinically significant respiratory and cardiovascular conditions thought to be contributing to cough or likely to interfere in the conduct of the study.~5. Patient who in the investigator's opinion may need to start a pulmonay rehabilitation program during the study and/or patients who started/finished it within 3 months prior to Screening Visit.~6. Use of long-term oxygen therapy.~7. Patients in non-stable treatment with angiotensin-converting enzyme inhibitors or opiates.~8. Patients in treatment with mucolytics, antihistamines, expectorants or antitussive drugs including over-the-counter medication.~9. Patient who does not maintain regular day/night, waking/sleeping cycles including night shift workers.~10. Patient with clinically relevant abnormalities in the results of the physical examination at Visit 1 (Screening)~11. Patient with a history of hypersensitivity reaction to inhaled anticholinergics,sympathomimetic amines, or inhaled medication or any component thereof (including report of paradoxical bronchospasm).~12. Patient with known narrow-angle glaucoma, symptomatic bladder neck obstruction, acute urinary retention, or patients with symptomatic non-stable prostatic hypertrophy.~13. Patient with known non-controlled history of infection with human immunodeficiency virus (HIV) and/or active hepatitis~14. Current diagnosis of cancer other than basal or squamous cell skin cancer~15. Patient with any other serious or uncontrolled physical or mental dysfunction~16. Patient with a history (within 2 years prior to Screening Visit) of drug and/or alcohol abuse that may prevent study compliance based on investigator judgment.~17. Patient unlikely to be cooperative or that can not comply with the study procedures~18. Patient treated with any investigational drug within 30 days (or 6 half-lives, whichever is longer) prior to Visit 1 (Screening).~19. Patient who intend to use any concomitant medication not permitted by this protocol or who have not undergone the required stabilization periods for prohibited medication.~20. Any other conditions that, in the investigator's opinion, might indicate the patient to be unsuitable for the study.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 110 Years
- Healthy Volunteers: f

Study Arms:
- Aclidinium Bromide 400 μg (Type: EXPERIMENTAL): Aclidinium Bromide 400 μg twice daily by inhalation
- Placebo (Type: PLACEBO_COMPARATOR): placebo twice daily by inhalation

Based on this trial design, predict the completion outcome and termination type (if applicable).